Abstract
Four monoclonal-antibody-defined serum markers (CA15-3, HMFG1, HMFG2 and NCRC-11) were examined in five groups of subjects: controls, benign breast disease and stage I/II, stage III and metastatic breast cancer. None of the markers were significantly elevated in primary breast cancer (i.e. stage I/II or stage III) compared with controls or patients with benign breast disease. These markers therefore have no role in screening or in the diagnosis of primary breast cancer. CA15-3, HMFG2 and NCRC-11 were significantly increased in the patients with metastatic breast cancer (P less than 0.001), indicating a potential use in the diagnosis of symptomatic metastases. In patients with metastases, sequential changes in CA15-3 correlated significantly with clinical response to therapy. Thus CA15-3 is a powerful marker of response and in combination with other markers, may provide an objective measurement of response to therapy in patients with advanced breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 1127-32 |
| Number of pages | 6 |
| Journal | European journal of cancer (Oxford, England : 1990) |
| Volume | 26 |
| Issue number | 11-12 |
| Publication status | Published - 1990 |
Keywords
- Adult
- Aged
- Antibodies, Monoclonal
- Antigens, Tumor-Associated, Carbohydrate
- Biomarkers, Tumor
- Breast Neoplasms
- Female
- Humans
- Membrane Glycoproteins
- Middle Aged
- Mucin-1
- Neoplasm Staging
- Journal Article
- Research Support, Non-U.S. Gov't
